Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI Insight
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewHematologyOncology Open Access | 10.1172/jci.insight.142149

Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML

Zuzana Tothova,1 Anne-Laure Valton,2 Rebecca Gorelov,3 Mounica Vallurupalli,1 John M. Krill-Burger,3 Amie Holmes,4 Catherine C. Landers,3 J. Erika Haydu,3 Edyta Malolepsza,3 Christina R. Hartigan,3 Melanie Donahue,3 Katerina D. Popova,3 Sebastian H. J. Koochaki,1 Sergey V. Venev,2 Jeanne F. Rivera,5 Edwin Chen,5 Kasper Lage,3 Monica Schenone,3 Alan D. D'Andrea,6 Steven A. Carr,3 Elizabeth A. Morgan,7 Job Dekker,2 and Benjamin L. Ebert1

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Tothova, Z. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Valton, A. in: JCI | PubMed | Google Scholar |

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Gorelov, R. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Vallurupalli, M. in: JCI | PubMed | Google Scholar |

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Krill-Burger, J. in: JCI | PubMed | Google Scholar |

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Holmes, A. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Landers, C. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Haydu, J. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Malolepsza, E. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Hartigan, C. in: JCI | PubMed | Google Scholar |

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Donahue, M. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Popova, K. in: JCI | PubMed | Google Scholar |

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Koochaki, S. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Venev, S. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Rivera, J. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Chen, E. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Lage, K. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Schenone, M. in: JCI | PubMed | Google Scholar |

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by D'Andrea, A. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Carr, S. in: JCI | PubMed | Google Scholar |

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Morgan, E. in: JCI | PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Dekker, J. in: JCI | PubMed | Google Scholar |

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Biochemistry and Molecular Pharmacology, The University of Massachusetts Medical School, Worcester, United States of America

3Cancer Program, Broad Institute, Cambridge, United States of America

4Department of Radiation Oncology, Dana-Farber Cancder Institute, Boston, United States of America

5Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States of America

7Department of Pathology, Brigham and Women's Hospital, Boston, United States of America

Find articles by Ebert, B. in: JCI | PubMed | Google Scholar |

Published December 22, 2020 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.142149.
Copyright © 2020, Tothova et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published December 22, 2020 - Version history
View PDF
Abstract

The cohesin complex plays an essential role in chromosome maintenance and transcriptional regulation. Recurrent somatic mutations in the cohesin complex are frequent genetic drivers in cancer including myelodysplatic syndromes (MDS) and acute myeloid leukemia (AML). Here, using genetic dependency screens of STAG2-mutant AML, we identified DNA damage repair and replication as genetic dependencies in cohesin-mutant cells. We demonstrated increased levels of DNA damage and sensitivity of cohesin-mutant cells to PARP inhibition. We developed a mouse model of MDS in which Stag2 mutations arise as clonal secondary lesions in the background of clonal hematopoiesis driven by Tet2 mutations, and demonstrated selective depletion of cohesin-mutant cells with PARP inhibition in vivo. Finally, we demonstrated a shift from STAG2- to STAG1-containing cohesin complexes in cohesin-mutant cells, which is associated with longer DNA loop extrusion, more intermixing of chromatin compartments, and increased interaction with PARP and RPA proteins. Our findings inform the biology and therapeutic opportunities for cohesin-mutant malignancies.

Graphical Abstract
graphical abstract
Supplemental material

View

View Supplemental Data Table S1

View Supplemental Data Table S2

View Supplemental Data Table S3

Version history
  • Version 1 (December 22, 2020): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI Insight

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts